PsychoactiveMap

New York State Psychiatric Institute psychedelic research trials

Data as of 31 October 2026. Source: ClinicalTrials.gov records held by PsychoactiveMap, refreshed from a reviewed snapshot.

New York State Psychiatric Institute is listed with 13 registered studies counted here, in New York, United States. By compound: 4 psilocybin and 9 ketamine. By registry status: 1 recruiting, 1 not yet recruiting, 1 active, not recruiting, 7 completed and 3 terminated. By phase: 2 phase 1, 5 phase 2, 3 phase 3 and 3 phase 4. Reported start years run from 2009 (earliest) to 2026 (latest).

Institution name, city and country are copied from the research site linked to each registry record. A study counts once per institution, and a study tagged with more than one compound is counted under each compound.

Educational information, not medical advice. A registry listing is not evidence of safety, benefit or results, and it is not a recommendation. PsychoactiveMap does not recruit, screen or refer participants. Status and other details are copied from the registry and can be out of date, so check the registry record and speak to a qualified health professional before any decision. Read the full disclaimer.

At a glance

By compound

Compound hubStudies
Psilocybin4
Ketamine9

By registry status

StatusStudiesShare
Recruiting18%
Not yet recruiting18%
Active, not recruiting18%
Completed754%
Terminated323%

By phase

PhaseStudiesShare
Phase 1215%
Phase 2538%
Phase 3323%
Phase 4323%

Registered studies

All counted studies, newest start first. Dates may be estimated, including future dates; a listed date does not confirm that a study started. The order is not a ranking and says nothing about quality. Titles are quoted from the registry. Each ID links to its own ClinicalTrials.gov record, which has the eligibility criteria and contacts.

Title as registeredRegistry IDStatusPhaseRegistry datesCompound
Understanding the Role of the Kappa Opioid Receptor in Ketamine's Attenuation of Suicidal ThoughtsNCT07139106Not yet recruitingPhase 4Source start: 2026-10-01 (estimated)
Saved start 2026-02-01 differs from reported 2026-10-01; the saved day is not established by this observation.
Source date details

Start: 2026-10-01 (precision: day; source type: ESTIMATED; estimated)

Primary completion: 2028-10-01 (precision: day; source type: ESTIMATED; estimated)

Study completion: 2028-10-01 (precision: day; source type: ESTIMATED; estimated)

Observation retrieved: 2026-10-31T20:06:18.160Z; registry revision: 2026-08-03 (precision: day; source type: ACTUAL; actual). Source observations do not verify a different saved scalar or establish that an event occurred.

Ketamine
A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive DisorderNCT06793397RecruitingPhase 3Source start: 2025-12-10 (actual)
Source date details

Start: 2025-12-10 (precision: day; source type: ACTUAL; actual)

Primary completion: 2027-06-07 (precision: day; source type: ESTIMATED; estimated)

Study completion: 2027-08-09 (precision: day; source type: ESTIMATED; estimated)

Observation retrieved: 2026-10-31T20:06:17.780Z; registry revision: 2026-10-30 (precision: day; source type: ACTUAL; actual). Source observations do not verify a different saved scalar or establish that an event occurred.

Psilocybin
Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRDNCT05711940Active, not recruitingPhase 3Source start: 2023-02-14 (actual)
Source date details

Start: 2023-02-14 (precision: day; source type: ACTUAL; actual)

Primary completion: 2025-11-13 (precision: day; source type: ACTUAL; actual)

Study completion: 2026-12 (precision: month; source type: ESTIMATED; estimated)

Observation retrieved: 2026-10-31T20:06:16.639Z; registry revision: 2026-08-10 (precision: day; source type: ACTUAL; actual). Source observations do not verify a different saved scalar or establish that an event occurred.

Psilocybin
Efficacy, Safety, and Tolerability of COMP360 in Participants With TRDNCT05624268CompletedPhase 3Source start: 2023-01-24 (actual)
Saved start 2023-01-19 differs from reported 2023-01-24; the saved day is not established by this observation.
Source date details

Start: 2023-01-24 (precision: day; source type: ACTUAL; actual)

Primary completion: 2025-05-28 (precision: day; source type: ACTUAL; actual)

Study completion: 2026-04-15 (precision: day; source type: ACTUAL; actual)

Observation retrieved: 2026-10-31T20:06:16.599Z; registry revision: 2026-08-10 (precision: day; source type: ACTUAL; actual). Source observations do not verify a different saved scalar or establish that an event occurred.

Psilocybin
The Role of HNKs in the Antidepressant Effect of KetamineNCT03977675TerminatedPhase 1Source start: 2019-05-15 (actual)
Source date details

Start: 2019-05-15 (precision: day; source type: ACTUAL; actual)

Primary completion: 2020-07-02 (precision: day; source type: ACTUAL; actual)

Study completion: 2020-07-02 (precision: day; source type: ACTUAL; actual)

Observation retrieved: 2026-10-31T20:06:15.077Z; registry revision: 2021-01-22 (precision: day; source type: ACTUAL; actual). Source observations do not verify a different saved scalar or establish that an event occurred.

Ketamine
The Safety and Efficacy of Psilocybin in Participants With Treatment Resistant DepressionNCT03775200CompletedPhase 2Source start: 2019-03-01 (actual)
Source date details

Start: 2019-03-01 (precision: day; source type: ACTUAL; actual)

Primary completion: 2021-07-30 (precision: day; source type: ACTUAL; actual)

Study completion: 2021-09-27 (precision: day; source type: ACTUAL; actual)

Observation retrieved: 2026-10-31T20:06:14.687Z; registry revision: 2023-04-24 (precision: day; source type: ACTUAL; actual). Source observations do not verify a different saved scalar or establish that an event occurred.

Psilocybin
Randomized Controlled Trial of Intranasal Ketamine vs. Intranasal Midazolam in Individuals With OCDNCT02206776TerminatedPhase 2Source start: 2014-09 (type unknown)
Saved start 2014-09-01 differs from reported 2014-09; the saved day is not established by this observation.
Source date details

Start: 2014-09 (precision: month; source type: not reported; unknown)

Primary completion: 2015-05 (precision: month; source type: ACTUAL; actual)

Study completion: 2015-05 (precision: month; source type: ACTUAL; actual)

Observation retrieved: 2026-10-31T20:06:13.506Z; registry revision: 2017-05-03 (precision: day; source type: ACTUAL; actual). Source observations do not verify a different saved scalar or establish that an event occurred.

Ketamine
Biomarker Assessment of Glutamatergic Target EngagementNCT02134951CompletedPhase 4Source start: 2014-05 (type unknown)
Saved start 2014-05-01 differs from reported 2014-05; the saved day is not established by this observation.
Source date details

Start: 2014-05 (precision: month; source type: not reported; unknown)

Primary completion: 2015-10 (precision: month; source type: ACTUAL; actual)

Study completion: 2015-11 (precision: month; source type: ACTUAL; actual)

Observation retrieved: 2026-10-31T20:06:13.506Z; registry revision: 2018-08-17 (precision: day; source type: ACTUAL; actual). Source observations do not verify a different saved scalar or establish that an event occurred.

Ketamine
NMDA Antagonists in Bipolar DepressionNCT01833897CompletedPhase 4Source start: 2013-03 (type unknown)
Saved start 2013-03-01 differs from reported 2013-03; the saved day is not established by this observation.
Source date details

Start: 2013-03 (precision: month; source type: not reported; unknown)

Primary completion: 2014-07 (precision: month; source type: ACTUAL; actual)

Study completion: 2016-03 (precision: month; source type: ACTUAL; actual)

Observation retrieved: 2026-10-31T20:06:13.146Z; registry revision: 2016-06-01 (precision: day; source type: ESTIMATED; estimated). Source observations do not verify a different saved scalar or establish that an event occurred.

Ketamine
The Effect of Brief Potent Glutamatergic Modulation on Cocaine DependenceNCT01535937TerminatedPhase 1Source start: 2012-02 (actual)
Saved start 2012-02-01 differs from reported 2012-02; the saved day is not established by this observation.
Source date details

Start: 2012-02 (precision: month; source type: ACTUAL; actual)

Primary completion: 2017-01 (precision: month; source type: ACTUAL; actual)

Study completion: 2017-04 (precision: month; source type: ACTUAL; actual)

Observation retrieved: 2026-10-31T20:06:13.115Z; registry revision: 2019-05-01 (precision: day; source type: ACTUAL; actual). Source observations do not verify a different saved scalar or establish that an event occurred.

Ketamine
Ketamine in the Treatment of DepressionNCT01558063CompletedPhase 2Source start: 2012-02 (type unknown)
Saved start 2012-02-01 differs from reported 2012-02; the saved day is not established by this observation.
Source date details

Start: 2012-02 (precision: month; source type: not reported; unknown)

Primary completion: 2015-05 (precision: month; source type: ACTUAL; actual)

Study completion: 2019-10 (precision: month; source type: ACTUAL; actual)

Observation retrieved: 2026-10-31T20:06:13.115Z; registry revision: 2019-12-10 (precision: day; source type: ACTUAL; actual). Source observations do not verify a different saved scalar or establish that an event occurred.

Ketamine
Pilot Study of Ketamine in Adults With Obsessive-Compulsive Disorder (OCD)NCT01100255CompletedPhase 2Source start: 2010-04 (type unknown)
Saved start 2010-04-01 differs from reported 2010-04; the saved day is not established by this observation.
Source date details

Start: 2010-04 (precision: month; source type: not reported; unknown)

Primary completion: 2015-12 (precision: month; source type: ACTUAL; actual)

Study completion: 2015-12 (precision: month; source type: ACTUAL; actual)

Observation retrieved: 2026-10-31T20:06:12.737Z; registry revision: 2017-02-20 (precision: day; source type: ACTUAL; actual). Source observations do not verify a different saved scalar or establish that an event occurred.

Ketamine
Memantine Augmentation in Treatment-Resistant Adults With Obsessive-Compulsive DisorderNCT00956085CompletedPhase 2Source start: 2009-08 (type unknown)
Saved start 2009-08-01 differs from reported 2009-08; the saved day is not established by this observation.
Source date details

Start: 2009-08 (precision: month; source type: not reported; unknown)

Primary completion: 2015-12 (precision: month; source type: ACTUAL; actual)

Study completion: 2015-12 (precision: month; source type: ACTUAL; actual)

Observation retrieved: 2026-10-31T20:06:12.748Z; registry revision: 2017-06-21 (precision: day; source type: ACTUAL; actual). Source observations do not verify a different saved scalar or establish that an event occurred.

Ketamine

About this data

Compound tags come from automated matching of the registry search term and have not been checked record by record. Counts are of registered studies, not of people, results or approvals. A registry listing is not evidence of safety, benefit or results.

Substance hubs for these compounds

Psilocybin | Ketamine

Country hub: United States

All trial hubs | Learn | Disclaimer